Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial

With no approved treatments in Japan for the prevention of hereditary angioedema (HAE) attacks, there is a significant unmet need for long‐term prophylactic therapies for Japanese patients with HAE. Berotralstat (BCX7353) is an oral, once‐daily, highly selective inhibitor of plasma kallikrein in development for prophylaxis of angioedema attacks in HAE patients.

[1]  William H. Yang,et al.  Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. , 2020, The Journal of allergy and clinical immunology.

[2]  J. Bernstein,et al.  US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. , 2020, The journal of allergy and clinical immunology. In practice.

[3]  P. Keith,et al.  The International/Canadian Hereditary Angioedema Guideline , 2019, Allergy, Asthma & Clinical Immunology.

[4]  L. Brussino,et al.  Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research , 2019, Drugs in context.

[5]  Sumimasa Nagai,et al.  Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan , 2019, International journal of molecular sciences.

[6]  T. Horiuchi,et al.  The use of tranexamic acid for on‐demand and prophylactic treatment of hereditary angioedema—A systematic review , 2018, Journal of Cutaneous Immunology and Allergy.

[7]  T. Horiuchi.  Hereditary Angioedema from 1888 to 2018 -Progress and Problems , 2018, Internal medicine.

[8]  William J. Cardarelli.  Economic burden limiting proper healthcare delivery, management, and improvement of patient outcomes. , 2018, The American journal of managed care.

[9]  M. Triggiani,et al.  Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema , 2018, The New England journal of medicine.

[10]  Yusuke Suzuki,et al.  Suffocation due to Acute Airway Edema in a Patient with Hereditary Angioedema Highlighted the Need for Urgent Improvements in Treatment Availability in Japan , 2018, Internal medicine.

[11]  R. Lockey,et al.  The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update , 2018, Allergy.

[12]  P. Martus,et al.  The Angioedema Quality of Life Questionnaire (AE‐QoL) – assessment of sensitivity to change and minimal clinically important difference , 2016, Allergy. European Journal of Allergy and Clinical Immunology.

[13]  B. Zuraw,et al.  HAE Pathophysiology and Underlying Mechanisms , 2016, Clinical Reviews in Allergy & Immunology.

[14]  K. Beusterien,et al.  Burden of Illness in Hereditary Angioedema: A Conceptual Model. , 2015, Acta dermato-venereologica.

[15]  Y. Tomino,et al.  Clinical manifestations, diagnosis, and treatment of hereditary angioedema: survey data from 94 physicians in Japan. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[16]  A. Banerji.  The burden of illness in patients with hereditary angioedema. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[17]  J. Bernstein,et al.  US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. , 2013, The journal of allergy and clinical immunology. In practice.

[18]  P. Martus,et al.  Development and construct validation of the angioedema quality of life questionnaire , 2012, Allergy.

[19]  K. Bork,et al.  Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. , 2012, The Journal of allergy and clinical immunology.

[20]  W. Lumry,et al.  The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. , 2010, Allergy and asthma proceedings.

[21]  A. Kaplan,et al.  The bradykinin-forming cascade and its role in hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[22]  Z. Shariat-Madar,et al.  Human plasma kallikrein-kinin system: physiological and biochemical parameters. , 2009, Cardiovascular & hematological agents in medicinal chemistry.

[23]  K. Bork,et al.  Hereditary angioedema: new findings concerning symptoms, affected organs, and course. , 2006, The American journal of medicine.

[24]  Y. Hochberg.  A sharper Bonferroni procedure for multiple tests of significance , 1988 .

[25]  Tetsurou Yamamoto,et al.  Guideline for hereditary angioedema (HAE) 2010 by the Japanese Association for Complement Research - secondary publication. , 2012, Allergology international : official journal of the Japanese Society of Allergology.